Navigation Links
ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
Date:9/4/2007

Transfer Paves the Way for the Phase III Clinical Development and

Commercialization of THR-100 in Developing Countries

LEUVEN, Belgium, September 4 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, today announced the successful completion of the technology transfer to Bharat Biotech International Limited (Hyderabad, India) for the manufacture of THR-100, a novel variant of Recombinant Staphylokinase.THR-100 is a thrombolytic agent developed for the treatment of acute myocardial infarction (AMI or heart attack) and other vascular diseases, based on its ability to dissolve blood clots.

ThromboGenics had earlier (December 6, 2006) announced the completion of a license agreement with Bharat Biotech to manufacture, develop and commercialize THR-100 as a replacement for established thrombolytics, such as streptokinase and urokinase, in developing countries. THR-100 has completed Phase II clinical trials in Europe for treatment of AMI, and is expected to enter Phase III in India later this year.

With this announcement, ThromboGenics has completed the successful transfer of its robust, proprietary and scaled-up process for the production of THR-100, a recombinant protein. Bharat Biotech will use its manufacturing capabilities, along with technological expertise acquired from ThromboGenics, to produce clinical-grade material for upcoming clinical trials. By absorbing the THR-100 manufacturing technology at different scales, while maintaining required yield and purity, Bharat Biotech has demonstrated its ability and capacity to produce this recombinant protein with the desired performance, quality and cost-effectiveness.

Prof. Desire Collen, CEO of ThromboGenics, commented on today's announcement: "We are pleased that ThromboGenics and Bharat Biotech have successfully completed the technology transfer needed for the production of THR-100. Transfer of biopharmaceutical production technology from one company to another, or from one country to another, can be a complex process. This milestone proves the commitment from both sides to use their substantial scientific skills to supply THR-100, a novel recombinant therapeutic, to the developing world. With this successful collaboration, we look forward to moving this unique thrombolytic agent quickly into the clinic and toward commercialization."

Commenting on the technology transfer, Dr. Krishna M. Ella, Chairman and Managing Director of Bharat Biotech, said, "Successful transfer of technology from ThromboGenics to Bharat Biotech is a significant milestone in the development of THR-100 as a novel thrombolytic agent. Bharat Biotech has significant expertise in executing technology transfer processes from U.S. and EU companies. We are highly excited about further clinical development of THR-100 and its commercialization."

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics also has one program, TB-402 (Anti-Factor VIII), in Phase I clinical trials, and three other drug candidates in preclinical development with preclinical proof-of-principle demonstrated. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland, and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About Bharat Biotech International Limited

Bharat Biotech International Limited is a multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. The Company, established in 1996, is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research. Bharat Biotech is one of the first biopharma facilities in India to be audited and approved by the Korean FDA. Bharat Biotech sprawls over a picturesque campus at Genome Valley, Hyderabad, built with an investment of over US $100 million. The facility's Manufacturing, Control Procedures and Protocols conform to the stringent standards laid down by internationally recognized institutions such as USFDA, UKMCA and WHO. The Company's product line includes INDIKINASE(TM) recombinant Streptokinase, REGEN-D(TM) recombinant Epidermal Growth Factor, TYPBAR(TM) Vi Capsular Polysaccharide Typhoid vaccine, BIOGIT(TM) probiotic yeast, and INDIRAB(TM) anti-rabies vaccine. Bharat Biotech also has a strong pipeline of vaccines to combat Malaria, Rotavirus and Japanese Encephalitis. More information is available at http://www.bharatbiotech.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.

For further information, please.contact

ThromboGenics

Prof. Desire Collen, CEO

Tel: +32-0-16-34-61-94

Stuart Laermer, Chief Business Officer

Tel: +1-212-201-0920

Bharat Biotech International Limited

Dr. V. Krishna Mohan, President

Tel: +91-40-2348-0567

Citigate Dewe Rogerson

David Dible / Valerie Auffray

Tel: +44-0-207-638-95-71


'/>"/>
SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... 2017 , ... When James Sherley, was notified earlier this year that his company Asymmetrex ... 2017 by The Silicon Review , he was not surprised as others might be. ... but this recognition by Silicon Valley was particularly meaningful. Our selection by ...
(Date:5/16/2017)... ... 16, 2017 , ... Cynvenio Biosystems, Inc. a ... Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known ... and accurately identify tumor-related genetic mutations that can be treated with targeted therapies. ...
(Date:5/15/2017)... (PRWEB) , ... May 15, 2017 , ... Tunnell ... in a presentation of “The Key Role of Specifications in Process Validation,” at the ... Philadelphia . The event will bring together leaders from the pharmaceutical and biotech industries ...
(Date:5/15/2017)... , May 15, 2017  IBM (NYSE: IBM ... can stretch double-stranded DNA molecules with the potential ... This technology complements the IBM Research,s ... such as exosomes and which may also contain ... uses an array of diamond shaped micropillars 1 ...
Breaking Biology Technology:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
Breaking Biology News(10 mins):